2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
4
Neoplasm Metastasis
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Myeloid, Chronic-Phase
2
Glioblastoma
2
Brain Neoplasms
2
Adenocarcinoma of Lung
2
Vaping
1
Urinary Bladder Neoplasms
1
Tobacco Use Disorder
1
Stomach Neoplasms
1
Solid Tumor
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oligodendroglioma
1
Neoplasms by Histologic Type
1
NSCLC
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Interventions
Prednisolone
1
BID protein, human
1
Androgen Antagonists
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Abiraterone Acetate
×
BID protein, human
×
Clear all
NCT06768255
2025-01-10
mCRPC
Fudan University
Phase 3
Not yet recruiting
400 enrolled